MLL gene rearrangement in acute myelogenous leukemia after exposure to tegafur/uracil
We report a case of acute myelogenous leukemia (AML) with MLL (myeloid-lymphoid leukemia or mixed-lineage leukemia) gene rearrangement after exposure to tegafur/uracil. Cytogenetic and clinical findings in this patient: t(11;17) (q23;q25), AML-M4 morphology, development of AML within a short latent...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2002-02, Vol.75 (2), p.178-181 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 181 |
|---|---|
| container_issue | 2 |
| container_start_page | 178 |
| container_title | International journal of hematology |
| container_volume | 75 |
| creator | FUKUSHIMA, Toshihiro YOSHIO, Nobuyuki NOTO, Yutaka KIDA, Hiroshi |
| description | We report a case of acute myelogenous leukemia (AML) with MLL (myeloid-lymphoid leukemia or mixed-lineage leukemia) gene rearrangement after exposure to tegafur/uracil. Cytogenetic and clinical findings in this patient: t(11;17) (q23;q25), AML-M4 morphology, development of AML within a short latent period after first exposure to tegafur/uracil, and good response to remission induction chemotherapy but short remission duration, have been considered typical features of therapy-related acute myelogenous leukemia (t-AML) after exposure to topoisomerase II-targeting agents. This case report suggests that t-AML may develop after exposure to tegafur/uracil and that MLL gene rearrangement may not necessarily be specific to t-AML after exposure to topoisomerase II-targeting agents. |
| doi_str_mv | 10.1007/bf02982024 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_217394898</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1879938291</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-3821c7a49b3c797d819c43c45c06e520f6cbcbf98918f5997bc16e8fbcc8036a3</originalsourceid><addsrcrecordid>eNpF0M1LwzAYx_EgipvTi3-ABMGLUJeXpkmOOpwKFS_uXNLsyejsy0wacP-9lVV2ei4ffg98Ebqm5IESIuelI0wrRlh6gqZUZSLhUqanaEo0E4mQlEzQRQhbQqgkqTxHE0o11ywTU7R6z3O8gRawB-O9aTfQQNvjqsXGxh5ws4e6G0AXA64hfkFTGWxcDx7Dz64L0QPuO9zDxrjo59EbW9WX6MyZOsDVeGdotXz-XLwm-cfL2-IxTyzXvE-4YtRKk-qSW6nlWlFtU25TYUkGghGX2dKWTitNlRNay9LSDJQrrVWEZ4bP0O1hd-e77wihL7Zd9O3wsmBUcp0qrQZ0f0DWdyF4cMXOV43x-4KS4i9g8bT8Dzjgm3Exlg2sj3QsNoC7EZhgTe2GZLYKR8cFy6SU_Bc3bnfQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217394898</pqid></control><display><type>article</type><title>MLL gene rearrangement in acute myelogenous leukemia after exposure to tegafur/uracil</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>FUKUSHIMA, Toshihiro ; YOSHIO, Nobuyuki ; NOTO, Yutaka ; KIDA, Hiroshi</creator><creatorcontrib>FUKUSHIMA, Toshihiro ; YOSHIO, Nobuyuki ; NOTO, Yutaka ; KIDA, Hiroshi</creatorcontrib><description>We report a case of acute myelogenous leukemia (AML) with MLL (myeloid-lymphoid leukemia or mixed-lineage leukemia) gene rearrangement after exposure to tegafur/uracil. Cytogenetic and clinical findings in this patient: t(11;17) (q23;q25), AML-M4 morphology, development of AML within a short latent period after first exposure to tegafur/uracil, and good response to remission induction chemotherapy but short remission duration, have been considered typical features of therapy-related acute myelogenous leukemia (t-AML) after exposure to topoisomerase II-targeting agents. This case report suggests that t-AML may develop after exposure to tegafur/uracil and that MLL gene rearrangement may not necessarily be specific to t-AML after exposure to topoisomerase II-targeting agents.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/bf02982024</identifier><identifier>PMID: 11939265</identifier><language>eng</language><publisher>Tokyo: Springer</publisher><subject>Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic - administration & dosage ; Antimetabolites, Antineoplastic - adverse effects ; Biological and medical sciences ; Chromosomes, Human, Pair 11 ; Chromosomes, Human, Pair 17 ; Colonic Neoplasms - complications ; Colonic Neoplasms - drug therapy ; Drug toxicity and drugs side effects treatment ; Gene Rearrangement ; Humans ; Leukemia, Myeloid, Acute - chemically induced ; Leukemia, Myeloid, Acute - genetics ; Male ; Medical sciences ; Neoplasms, Second Primary - chemically induced ; Neoplasms, Second Primary - genetics ; Pharmacology. Drug treatments ; Tegafur - administration & dosage ; Tegafur - adverse effects ; Topoisomerase II Inhibitors ; Toxicity: blood ; Translocation, Genetic</subject><ispartof>International journal of hematology, 2002-02, Vol.75 (2), p.178-181</ispartof><rights>2002 INIST-CNRS</rights><rights>The Japanese Society of Hematology 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-3821c7a49b3c797d819c43c45c06e520f6cbcbf98918f5997bc16e8fbcc8036a3</citedby><cites>FETCH-LOGICAL-c393t-3821c7a49b3c797d819c43c45c06e520f6cbcbf98918f5997bc16e8fbcc8036a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13526777$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11939265$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FUKUSHIMA, Toshihiro</creatorcontrib><creatorcontrib>YOSHIO, Nobuyuki</creatorcontrib><creatorcontrib>NOTO, Yutaka</creatorcontrib><creatorcontrib>KIDA, Hiroshi</creatorcontrib><title>MLL gene rearrangement in acute myelogenous leukemia after exposure to tegafur/uracil</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><description>We report a case of acute myelogenous leukemia (AML) with MLL (myeloid-lymphoid leukemia or mixed-lineage leukemia) gene rearrangement after exposure to tegafur/uracil. Cytogenetic and clinical findings in this patient: t(11;17) (q23;q25), AML-M4 morphology, development of AML within a short latent period after first exposure to tegafur/uracil, and good response to remission induction chemotherapy but short remission duration, have been considered typical features of therapy-related acute myelogenous leukemia (t-AML) after exposure to topoisomerase II-targeting agents. This case report suggests that t-AML may develop after exposure to tegafur/uracil and that MLL gene rearrangement may not necessarily be specific to t-AML after exposure to topoisomerase II-targeting agents.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antimetabolites, Antineoplastic - administration & dosage</subject><subject>Antimetabolites, Antineoplastic - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Chromosomes, Human, Pair 11</subject><subject>Chromosomes, Human, Pair 17</subject><subject>Colonic Neoplasms - complications</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Gene Rearrangement</subject><subject>Humans</subject><subject>Leukemia, Myeloid, Acute - chemically induced</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neoplasms, Second Primary - chemically induced</subject><subject>Neoplasms, Second Primary - genetics</subject><subject>Pharmacology. Drug treatments</subject><subject>Tegafur - administration & dosage</subject><subject>Tegafur - adverse effects</subject><subject>Topoisomerase II Inhibitors</subject><subject>Toxicity: blood</subject><subject>Translocation, Genetic</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpF0M1LwzAYx_EgipvTi3-ABMGLUJeXpkmOOpwKFS_uXNLsyejsy0wacP-9lVV2ei4ffg98Ebqm5IESIuelI0wrRlh6gqZUZSLhUqanaEo0E4mQlEzQRQhbQqgkqTxHE0o11ywTU7R6z3O8gRawB-O9aTfQQNvjqsXGxh5ws4e6G0AXA64hfkFTGWxcDx7Dz64L0QPuO9zDxrjo59EbW9WX6MyZOsDVeGdotXz-XLwm-cfL2-IxTyzXvE-4YtRKk-qSW6nlWlFtU25TYUkGghGX2dKWTitNlRNay9LSDJQrrVWEZ4bP0O1hd-e77wihL7Zd9O3wsmBUcp0qrQZ0f0DWdyF4cMXOV43x-4KS4i9g8bT8Dzjgm3Exlg2sj3QsNoC7EZhgTe2GZLYKR8cFy6SU_Bc3bnfQ</recordid><startdate>20020201</startdate><enddate>20020201</enddate><creator>FUKUSHIMA, Toshihiro</creator><creator>YOSHIO, Nobuyuki</creator><creator>NOTO, Yutaka</creator><creator>KIDA, Hiroshi</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20020201</creationdate><title>MLL gene rearrangement in acute myelogenous leukemia after exposure to tegafur/uracil</title><author>FUKUSHIMA, Toshihiro ; YOSHIO, Nobuyuki ; NOTO, Yutaka ; KIDA, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-3821c7a49b3c797d819c43c45c06e520f6cbcbf98918f5997bc16e8fbcc8036a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antimetabolites, Antineoplastic - administration & dosage</topic><topic>Antimetabolites, Antineoplastic - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Chromosomes, Human, Pair 11</topic><topic>Chromosomes, Human, Pair 17</topic><topic>Colonic Neoplasms - complications</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Gene Rearrangement</topic><topic>Humans</topic><topic>Leukemia, Myeloid, Acute - chemically induced</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neoplasms, Second Primary - chemically induced</topic><topic>Neoplasms, Second Primary - genetics</topic><topic>Pharmacology. Drug treatments</topic><topic>Tegafur - administration & dosage</topic><topic>Tegafur - adverse effects</topic><topic>Topoisomerase II Inhibitors</topic><topic>Toxicity: blood</topic><topic>Translocation, Genetic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FUKUSHIMA, Toshihiro</creatorcontrib><creatorcontrib>YOSHIO, Nobuyuki</creatorcontrib><creatorcontrib>NOTO, Yutaka</creatorcontrib><creatorcontrib>KIDA, Hiroshi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FUKUSHIMA, Toshihiro</au><au>YOSHIO, Nobuyuki</au><au>NOTO, Yutaka</au><au>KIDA, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MLL gene rearrangement in acute myelogenous leukemia after exposure to tegafur/uracil</atitle><jtitle>International journal of hematology</jtitle><addtitle>Int J Hematol</addtitle><date>2002-02-01</date><risdate>2002</risdate><volume>75</volume><issue>2</issue><spage>178</spage><epage>181</epage><pages>178-181</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>We report a case of acute myelogenous leukemia (AML) with MLL (myeloid-lymphoid leukemia or mixed-lineage leukemia) gene rearrangement after exposure to tegafur/uracil. Cytogenetic and clinical findings in this patient: t(11;17) (q23;q25), AML-M4 morphology, development of AML within a short latent period after first exposure to tegafur/uracil, and good response to remission induction chemotherapy but short remission duration, have been considered typical features of therapy-related acute myelogenous leukemia (t-AML) after exposure to topoisomerase II-targeting agents. This case report suggests that t-AML may develop after exposure to tegafur/uracil and that MLL gene rearrangement may not necessarily be specific to t-AML after exposure to topoisomerase II-targeting agents.</abstract><cop>Tokyo</cop><pub>Springer</pub><pmid>11939265</pmid><doi>10.1007/bf02982024</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2002-02, Vol.75 (2), p.178-181 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_journals_217394898 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Aged Aged, 80 and over Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - adverse effects Biological and medical sciences Chromosomes, Human, Pair 11 Chromosomes, Human, Pair 17 Colonic Neoplasms - complications Colonic Neoplasms - drug therapy Drug toxicity and drugs side effects treatment Gene Rearrangement Humans Leukemia, Myeloid, Acute - chemically induced Leukemia, Myeloid, Acute - genetics Male Medical sciences Neoplasms, Second Primary - chemically induced Neoplasms, Second Primary - genetics Pharmacology. Drug treatments Tegafur - administration & dosage Tegafur - adverse effects Topoisomerase II Inhibitors Toxicity: blood Translocation, Genetic |
| title | MLL gene rearrangement in acute myelogenous leukemia after exposure to tegafur/uracil |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T07%3A16%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MLL%20gene%20rearrangement%20in%20acute%20myelogenous%20leukemia%20after%20exposure%20to%20tegafur/uracil&rft.jtitle=International%20journal%20of%20hematology&rft.au=FUKUSHIMA,%20Toshihiro&rft.date=2002-02-01&rft.volume=75&rft.issue=2&rft.spage=178&rft.epage=181&rft.pages=178-181&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/bf02982024&rft_dat=%3Cproquest_cross%3E1879938291%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217394898&rft_id=info:pmid/11939265&rfr_iscdi=true |